2026-10-25
Glass House Brands clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,813 +0.55%
S&P 7,744 +0.28%
GOLD $4,040 −0.28%
BTC $80,120 −0.85%
VIX 16.91 −3.48%
latest tape · as of 06:01 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Glass House Brands Inc.
GLASF · OQX · USD · Market cap $917M · 357 employees
Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States.
Not yet scored11.81 USD
Price as of 7 Sep 2026Daily close, not a live quoteLast reviewed 52 days ago
Screened 2026-09-07 · the tape above runs as of 06:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price11.81 USD at the 7 Sep 2026 close
- Our ratingOvervalued, current read accumulation
- Ethical screenNot yet scored
- Last reviewed7 Sep 2026 (52 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 11.81 against the desk's fair-value range, base estimate 9.19, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price11.81 USD
Fair value9.19
Ethical score70.0/100
RatingOVERVALUED
Our investment reviews on this name
2026-07-02Read Accumulation13.25-10.9% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Glass House Brands Inc. holds its Accumulation at $11.81. Elevated stress, defensive posture warranted, held for 8 days.
| Phase | Accumulation |
| Quantitative state | Elevated stress, defensive posture warranted, held for 8 days |
| Price at the screen | $11.81 |
| Valuation | N/A trailing · 44.57 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.51 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 10.02% | Below 33% | Interest-bearing debt is just 10.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 2.61% | Below 33% | Cash held in interest-bearing accounts and securities is 2.6% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Glass House Brands clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Glass House Brands clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 10%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads OVERVALUED: it trades above our $9.19 fair value estimate.
Fair value range in USD, drawn from the 2026-09-07 screen. The gold marker is the market price at the same screen. The price runs 22.2% above the base estimate.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-07 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCannabis Shops Still Deep in the Red
Picture a grower running its own stores and selling bulk flower to other retailers, yet still reporting revenue down 10 percent and a 21 percent loss margin. Glass House trades at 44.6 times forward earnings with return on equity at minus 20 percent, well above our fair value of 9.19 against the current 11.81 price. The ethical screen clears it, but the numbers show a business that has not yet turned consistent cash.
The two-analyst median target of 16 sits even higher, yet offers little comfort when growth is negative and the company remains unprofitable. A premium multiple on shrinking sales rarely ends well in a market this fragmented and heavily regulated.
Margins stay thin while competition and state rules keep shifting, so any rebound in volumes could vanish quickly. The current price leaves no margin of safety. Analysis, not advice.
| Forward P/E | 44.6xexpensive: the price assumes strong growth ahead |
| EPS, trailing | -0.60 |
| EPS, forward | 0.27 |
| Revenue growth | -9.6%revenue is shrinking |
| Profit margin | -20.7%currently unprofitable |
| Return on equity | -20.4%not currently earning a positive return on equity |
| FCF yield | -2.59% |
| Debt to equity | 0.42minimal debt: a conservative balance sheet |
| Current ratio | 1.85healthy short-term liquidity |
| Beta | 0.51steadier than the market |
| 52-week range | 4.55 - 13.93 |
| Market cap | $917M |
| Employees | 357 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeGLASF trades on OQX. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-18
Accumulation $11.81
+0.0% Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-10-02
Accumulation $11.81
+0.0% Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-08-30
Accumulation $11.81
+0.0% Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-07-31
Accumulation $11.81
-10.9% Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 10.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-07-18
Accumulation $13.25
+0.0% Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-07-03
Accumulation $13.25
+0.0% Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02
Accumulation $13.25
Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- New Analyst Coverage Puts These 5 Stocks in the Spotlight Zacks · 15 Jul 2026
- UG Outperforms Industry in 6 Months: Buy, Sell or Hold the Stock? Zacks · 8 Jul 2026
- Should Glass House Brands’ NYSE Debut and Medical Pivot Reshape the GLAS Investment Narrative? Simply Wall St. · 4 Jul 2026
- Cannabis Stocks Pop As Another U.S. Company Applies to List on NYSE Moby · 18 Jun 2026
- Assessing Glass House Brands (OTCPK:GLAS.F) Valuation After Strong Recent Share Price Momentum Simply Wall St. · 9 Jun 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
PCRXPacira BioSciences, Inc.
ESPREsperion Therapeutics, Inc.
AMPHAmphastar Pharmaceuticals, Inc.
COLLCollegium Pharmaceutical, Inc.
HROWHarrow, Inc.
PAHCPhibro Animal Health Corporation
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.35 | +36.9% | · | $1,369 | +36.9% |
| 2 months | $8.11 | +57.8% | · | $1,578 | +57.8% |
| 3 months | $7.61 | +68.2% | · | $1,682 | +68.2% |
| 6 months | $5.80 | +120.8% | · | $2,208 | +120.8% |
| 1 year | $5.40 | +137.0% | · | $2,370 | +137.0% |
| 2 years | $7.14 | +79.4% | · | $1,794 | +79.4% |
| 3 years | $4.15 | +208.7% | · | $3,087 | +208.7% |
| 5 years | $9.96 | +28.5% | · | $1,285 | +28.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever GLASF does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.